SEARCH

SEARCH BY CITATION

References

  • Bagga, S., Bracht, J., Hunter, S., Massirer, K., Holtz, J., Eachus, R. & Pasquinelli, A.E. (2005) Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell, 122, 553563.
  • Bergsagel, P.L., Kuehl, W.M., Zhan, F.H., Sawyer, J., Barlogie, B. & Shaughnessy, J. (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood, 106, 296303.
  • Bierie, B. & Moses, H.L. (2006) TGF-beta and cancer. Cytokine & Growth Factor Reviews, 17, 2940.
  • Boyd, K.D., Ross, F.M., Chiecchio, L., Dagrada, G.P., Konn, Z.J., Tapper, W.J., Walker, B.A., Wardell, C.P., Gregory, W.M., Szubert, A.J., Bell, S.E., Child, J.A., Jackson, G.H., Davies, F.E. & Morgan, G.J. (2012) A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia, 26, 349355.
  • Calin, G.A. & Croce, C.M. (2006a) MicroRNA signatures in human cancers. Nature Reviews Cancer, 6, 857866.
  • Calin, G.A. & Croce, C.M. (2006b) MicroRNA-cancer connection: the beginning of a new tale. Cancer Research, 66, 73907394.
  • Caramuta, S., Egyhazi, S., Rodolfo, M., Witten, D., Hansson, J., Larsson, C. & Lui, W.O. (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. The Journal of Investigative Dermatology, 130, 20622070.
  • Chang, T.C., Yu, D., Lee, Y.S., Wentzel, E.A., Arking, D.E., West, K.M., Dang, C.V., Thomas-Tikhonenko, A. & Mendell, J.T. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nature Genetics, 40, 4350.
  • Chen, L., Li, C., Zhang, R., Gao, X., Qu, X., Zhao, M., Qiao, C., Xu, J. & Li, J. (2011) miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma. Cancer Letters, 309, 6270.
  • Chi, J., Ballabio, E., Chen, X.H., Kusec, R., Taylor, S., Hay, D., Tramonti, D., Saunders, N.J., Littlewood, T., Pezzella, F., Boultwood, J., Wainscoat, J.S., Hatton, C.S. & Lawrie, C.H. (2011) MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biology Direct, 6, 23.
  • Chng, W.J., Huang, G.F., Chung, T.H., Ng, S.B., Gonzalez-Paz, N., Troska-Price, T., Mulligan, G., Chesi, M., Bergsagel, P.L. & Fonseca, R. (2011) Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia, 25, 10261035.
  • Corbetta, S., Vaira, V., Guarnieri, V., Scillitani, A., Eller-Vainicher, C., Ferrero, S., Vicentini, L., Chiodini, I., Bisceglia, M., Beck-Peccoz, P., Bosari, S. & Spada, A. (2010) Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocrine-Related Cancer, 17, 135146.
  • Costinean, S., Zanesi, N., Pekarsky, Y., Tili, E., Volinia, S., Heerema, N. & Croce, C.M. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proceedings of the National Academy of Sciences of the USA, 103, 70247029.
  • Decaux, O., Lode, L., Magrangeas, F., Charbonnel, C., Gouraud, W., Jezequel, P., Attal, M., Harousseau, J.L., Moreau, P., Bataille, R., Campion, L., Avert-Loiseau, H. & Minvielle, S. (2008) Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myelome. Journal of Clinical Oncology, 26, 47984805.
  • Deng, Z.B., Zhu, W., Lu, C.M., Shi, Q., Ju, S.G., Ma, H.B., Xu, Y. & Zhang, X.G. (2004) An agonist human ICOS monoclonal antibody that induces T cell activation and inhibits proliferation of a myeloma cell line. Hybridoma and Hybridomics, 23, 176182.
  • Dews, M., Homayouni, A., Yu, D., Murphy, D., Sevignani, C., Wentzel, E., Furth, E.E., Lee, W.M., Enders, G.H., Mendell, J.T. & Thomas-Tikhonenko, A. (2006) Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nature Genetics, 38, 10601065.
  • Dickens, N.J., Walker, B.A., Leone, P.E., Johnson, D.C., Brito, J.L., Zeisig, A., Jenner, M.W., Boyd, K.D., Gonzalez, D., Gregory, W.M., Ross, F.M., Davies, F.E. & Morgan, G.J. (2010) Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clinical Cancer Research, 16, 18561864.
  • Friedman, R.C., Farh, K.K., Burge, C.B. & Bartel, D.P. (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Research, 19, 92105.
  • Gerrits, A., Walasek, M.A., Olthof, S., Weersing, E., Ritsema, M., Zwart, E., van Os, R., Bystrykh, L.V. & de Haan, G. (2012) Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood, 119, 377387.
  • Guo, S., Lu, J., Schlanger, R., Zhang, H., Wang, J.Y., Fox, M.C., Purton, L.E., Fleming, H.H., Cobb, B., Merkenschlager, M., Golub, T.R. & Scadden, D.T. (2010) MicroRNA miR-125a controls hematopoietic stem cell number. Proceedings of the National Academy of Sciences of the USA, 107, 1422914234.
  • Gutierrez, N.C., Sarasquete, M.E., Misiewicz-Krzeminska, I., Delgado, M., De Las, Rivas.J., Ticona, F.V., Ferminan, E., Martin-Jimenez, P., Chillon, C., Risueno, A., Hernandez, J.M., Garcia-Sanz, R., Gonzalez, M. & San Miguel, J.F. (2010) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 24, 629637.
  • Iqbal, J., Shen, Y., Liu, Y., Fu, K., Jaffe, E.S., Liu, C., Liu, Z., Lachel, C.M., Deffenbacher, K., Greiner, T.C., Vose, J.M., Bhagavathi, S., Staudt, L.M., Rimsza, L., Rosenwald, A., Ott, G., Delabie, J., Campo, E., Braziel, R.M., Cook, J.R., Tubbs, R.R., Gascoyne, R.D., Armitage, J.O., Weisenburger, D.D., McKeithan, T.W. & Chan, W.C. (2012) Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood, 119, 49394948.
  • Jamieson, N.B., Morran, D.C., Morton, J.P., Ali, A., Dickson, E.J., Carter, C.R., Sansom, O.J., Evans, T.R., McKay, C.J. & Oien, K.A. (2012) MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clinical Cancer Research, 18, 534545.
  • Jensen, N.F., Soekilde, R. & Stenvang, J. (2012) MicroRNAs related to intrinsic resistance to oxaliplatin and the irinotecan metabolite SN-38 in 10 colorectal cancer cell lines. Journal of Clinical Oncology, 30(Suppl. 4), abstr 524.
  • Jima, D.D., Zhang, J., Jacobs, C., Richards, K.L., Dunphy, C.H., Choi, W.W., Au, W.Y., Srivastava, G., Czader, M.B., Rizzieri, D.A., Lagoo, A.S., Lugar, P.L., Mann, K.P., Flowers, C.R., Bernal-Mizrachi, L., Naresh, K.N., Evens, A.M., Gordon, L.I., Luftig, M., Friedman, D.R., Weinberg, J.B., Thompson, M.A., Gill, J.I., Liu, Q., How, T., Grubor, V., Gao, Y., Patel, A., Wu, H., Zhu, J., Blobe, G.C., Lipsky, P.E., Chadburn, A. & Dave, S.S. (2010) Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs. Blood, 116, e118e127.
  • Jing, Q., Huang, S., Guth, S., Zarubin, T., Motoyama, A., Chen, J., Di Padova, F., Lin, S.C., Gram, H. & Han, J. (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell, 120, 623634.
  • Lee, K., Kunkeaw, N., Jeon, S.H., Lee, I., Johnson, B.H., Kang, G.Y., Bang, J.Y., Park, H.S., Leelayuwat, C. & Lee, Y.S. (2011) Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. RNA, 17, 10761089.
  • Lee, H., Park, C.S., Deftereos, G., Morihara, J., Stern, J.E., Hawes, S.E., Swisher, E., Kiviat, N.B. & Feng, Q. (2012) MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features. World Journal of Surgical Oncology, 10, 174.
  • Li, J.H., Xiao, X., Zhang, Y.N., Wang, Y.M., Feng, L.M., Wu, Y.M. & Zhang, Y.X. (2011) MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Gynecologic Oncology, 120, 145151.
  • Lionetti, M., Biasiolo, M., Agnelli, L., Todoerti, K., Mosca, L., Fabris, S., Sales, G., Deliliers, G.L., Bicciato, S., Lombardi, L., Bortoluzzi, S. & Neri, A. (2009) Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood, 114, e20e26.
  • Lionetti, M., Agnelli, L., Lombardi, L., Tassone, P. & Neri, A. (2012) MicroRNAs in the pathobiology of multiple myeloma. Current Cancer Drug Targets, 12, 823837.
  • Liu, X., Lv, X.B., Wang, X.P., Sang, Y., Xu, S., Hu, K., Wu, M., Liang, Y., Liu, P., Tang, J., Lu, W.H., Feng, Q.S., Chen, L.Z., Qian, C.N., Bei, J.X., Kang, T. & Zeng, Y.X. (2012) MiR-138 suppressed nasopharyngeal carcinoma growth and tumorigenesis by targeting the CCND1 oncogene. Cell Cycle, 11, 24952506.
  • Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., Downing, J.R., Jacks, T., Horvitz, H.R. & Golub, T.R. (2005) MicroRNA expression profiles classify human cancers. Nature, 435, 834838.
  • Michalek, J., Ocadlikova, D., Matejkova, E., Foltankova, V., Dudova, S., Slaby, O., Horvath, R., Pour, L. & Hajek, R. (2010) Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. British Journal of Haematology, 148, 859867.
  • Montes-Moreno, S., Martinez, N., Sanchez-Espiridion, B., Diaz Uriarte, R., Rodriguez, M.E., Saez, A., Montalban, C., Gomez, G., Pisano, D.G., Garcia, J.F., Conde, E., Gonzalez-Barca, E., Lopez, A., Mollejo, M., Grande, C., Martinez, M.A., Dunphy, C., Hsi, E.D., Rocque, G.B., Chang, J., Go, R.S., Visco, C., Xu-Monette, Z., Young, K.H. & Piris, M.A. (2011) miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy. Blood, 118, 10341040.
  • Morgan, G.J., Davies, F.E., Gregory, W.M., Cocks, K., Bell, S.E., Szubert, A.J., Navarro-Coy, N., Drayson, M.T., Owen, R.G., Feyler, S., Ashcroft, A.J., Ross, F., Byrne, J., Roddie, H., Rudin, C., Cook, G., Jackson, G.H. & Child, J.A. (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet, 376, 19891999.
  • Nordentoft, I., Birkenkamp-Demtroder, K., Agerbaek, M., Theodorescu, D., Ostenfeld, M.S., Hartmann, A., Borre, M., Orntoft, T.F. & Dyrskjot, L. (2012) miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Medical Genomics, 5, 40.
  • Novotny, G.W., Sonne, S.B., Nielsen, J.E., Jonstrup, S.P., Hansen, M.A., Skakkebaek, N.E., Rajpert-De Meyts, E., Kjems, J. & Leffers, H. (2007) Translational repression of E2F1 mRNA in carcinoma in situ and normal testis correlates with expression of the miR-17-92 cluster. Cell Death and Differentiation, 14, 879882.
  • O'Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C.V. & Mendell, J.T. (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435, 839843.
  • Ozata, D.M., Caramuta, S., Velazquez-Fernandez, D., Akcakaya, P., Xie, H., Hoog, A., Zedenius, J., Backdahl, M., Larsson, C. & Lui, W.O. (2011) The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocrine-Related Cancer, 18, 643655.
  • Peltier, H.J. & Latham, G.J. (2008) Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA, 14, 844852.
  • Pichiorri, F., Suh, S.S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J.P., Munker, R., Volinia, S., Boccadoro, M., Garzon, R., Palumbo, A., Aqeilan, R.I. & Croce, C.M. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the USA, 105, 1288512890.
  • van Rhee, F., Szymonifka, J., Anaissie, E., Nair, B., Waheed, S., Alsayed, Y., Petty, N., Shaughnessy, J.D. Jr, Hoering, A., Crowley, J. & Barlogie, B. (2010) Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy. Blood, 116, 12201227.
  • Sanchez-Vega, B. & Gandhi, V. (2009) Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). British Journal of Haematology, 144, 856864.
  • Selvanayagam, P., Blick, M., Narni, F., van Tuinen, P., Ledbetter, D.H., Alexanian, R., Saunders, G.F. & Barlogie, B. (1988) Alteration and abnormal expression of the c-myc oncogene in human multiple myeloma. Blood, 71, 3035.
  • Shaughnessy, J.D., Zhan, F.H., Burington, B.E., Huang, Y.S., Colla, S., Hanamura, I., Stewart, J.P., Kordsmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H.W., Epstein, J., Anaissie, E., Krishna, S.G., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. & Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 22762284.
  • Srinivasan, S., Patric, I.R. & Somasundaram, K. (2011) A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One, 6, e17438.
  • Walker, B.A., Leone, P.E., Chiecchio, L., Dickens, N.J., Jenner, M.W., Boyd, K.D., Johnson, D.C., Gonzalez, D., Dagrada, G.P., Protheroe, R.K., Konn, Z.J., Stockley, D.M., Gregory, W.M., Davies, F.E., Ross, F.M. & Morgan, G.J. (2010) A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood, 116, e56e65.
  • Wentz-Hunter, K.K. & Potashkin, J.A. (2011) The role of miRNAs as key regulators in the neoplastic microenvironment. Molecular Biology International, 2011, 839872.
  • Woods, K., Thomson, J.M. & Hammond, S.M. (2007) Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. Journal of Biological Chemistry, 282, 21302134.
  • Wu, P., Walker, B.A., Brewer, D., Gregory, W.M., Ashcroft, J., Ross, F.M., Jackson, G.H., Child, A.J., Davies, F.E. & Morgan, G.J. (2011) A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clinical Cancer Research, 17, 63476355.
  • Xiao, C., Calado, D.P., Galler, G., Thai, T.H., Patterson, H.C., Wang, J., Rajewsky, N., Bender, T.P. & Rajewsky, K. (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell, 131, 146159.
  • Xiao, C., Srinivasan, L., Calado, D.P., Patterson, H.C., Zhang, B., Wang, J., Henderson, J.M., Kutok, J.L. & Rajewsky, K. (2008) Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes. Nature Immunology, 9, 405414.
  • Xiao, F., Zuo, Z., Cai, G., Kang, S., Gao, X. & Li, T. (2009) miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Research, 37, D105D110.
  • Yu, S.L., Chen, H.Y., Chang, G.C., Chen, C.Y., Chen, H.W., Singh, S., Cheng, C.L., Yu, C.J., Lee, Y.C., Chen, H.S., Su, T.J., Chiang, C.C., Li, H.N., Hong, Q.S., Su, H.Y., Chen, C.C., Chen, W.J., Liu, C.C., Chan, W.K., Li, K.C., Chen, J.J. & Yang, P.C. (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell, 13, 4857.
  • Zhang, J., Jima, D.D., Jacobs, C., Fischer, R., Gottwein, E., Huang, G., Lugar, P.L., Lagoo, A.S., Rizzieri, D.A., Friedman, D.R., Weinberg, J.B., Lipsky, P.E. & Dave, S.S. (2009) Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood, 113, 45864594.
  • Zhao, J.J., Yang, J., Lin, J., Yao, N., Zhu, Y., Zheng, J., Xu, J., Cheng, J.Q., Lin, J.Y. & Ma, X. (2009) Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nervous System, 25, 1320.
  • Zhou, Y., Chen, L., Barlogie, B., Stephens, O., Wu, X., Williams, D.R., Cartron, M.A., van Rhee, F., Nair, B., Waheed, S., Pineda-Roman, M., Alsayed, Y., Anaissie, E. & Shaughnessy, J.D. Jr (2010) High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2. Proceedings of the National Academy of Sciences of the USA, 107, 79047909.